Indication

Recrudescent typhus

Recrudescent typhus, classically known as Brill-Zinsser disease, is a delayed, relapsing systemic infection caused by the reactivation of dormant *Rickettsia prowazekii* years or decades after an initial bout of epidemic louse-borne typhus. Read more about Recrudescent typhus

150 drugs 90 manufacturers

Advertisement

Drugs that treat it

Common Recrudescent typhus therapies.

Showing 64–72 of 150 drugs

Filter & compare in the drug finder →Opens the drug finder with Recrudescent typhus preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Recrudescent typhus.

Recrudescent typhus, classically known as Brill-Zinsser disease, is a delayed, relapsing systemic infection caused by the reactivation of dormant *Rickettsia prowazekii* years or decades after an initial bout of epidemic louse-borne typhus.

It primarily affects adults or elderly individuals who previously resided in endemic areas or experienced untreated primary epidemic typhus, often reactivating during periods of physiologic stress, nutritional compromise, or waning cell-mediated immunity.

Pathophysiologically, the bacteria persist within host endothelial and reticuloendothelial cells, with reactivation producing a milder systemic vasculitis compared to primary infection.

Defining clinical features include acute fever, chills, severe headache, and malaise, occasionally accompanied by a transient, faint maculopapular rash, while serving epidemiologically as an interepidemic human reservoir capable of transmitting the pathogen to lice.

Personalize your experience

Follow Recrudescent typhus and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it